This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Oklahoma
Licensed Oklahoma practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Oklahoma buyers need their own professional license and NPI; the wholesale distributor license is the supplier’s obligation, not the purchaser’s.
Oklahoma has legislated around investigational treatment more than most states: a right to try act in 2015, an individualized treatments expansion taking effect November 1, 2026, a stem cell research statute, and a public cord blood bank. None of these is a clinic authorization, and sorting out what each one actually covers is most of what an Oklahoma practice needs from this page.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Oklahoma? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | SB 933 (2026) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Oklahoma
ExaVeyra ships to licensed practices in all 50 states, Oklahoma included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Oklahoma professional license in good standing, verifiable through the Oklahoma State Board of Medical Licensure and Supervision lookup or the Oklahoma Board of Nursing portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- An Oklahoma Tax Commission sales tax permit and resale documentation if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Oklahoma licenses wholesale distributors through the State Board of Pharmacy under the Oklahoma Pharmacy Act and the Board’s facility rules, which implement the federal Drug Supply Chain Security Act. The rules are written facility by facility: a wholesale distributor may not distribute prescription drugs in, into, or out of Oklahoma unless each of its facilities is licensed, and a distributor shipping into Oklahoma must also be licensed by the state it ships from. The Board’s facility catalog separates wholesale distributors from manufacturers, repackagers, and third-party logistics providers. The license sits with the distributor, not with the purchasing practice.
Okla. Stat. tit. 59, § 353 et seq.; Okla. Admin. Code 535:20-7 · Oklahoma State Board of Pharmacy
Oklahoma regenerative-medicine law
Oklahoma enacted SB 933, codified at 63 O.S. §§ 3092.1 through 3092.6, effective 1 November 2026.
SB 933 is the third act in Oklahoma’s right to try line. The original Right to Try Act (HB 1074, 2015, 63 O.S. 3091.1 et seq.) lets manufacturers make Phase-1-cleared investigational drugs, biological products, and devices available to terminally ill patients. SB 933 adds the Right to Try for Individualized Treatments Act, effective November 1, 2026: a manufacturer operating within an eligible facility that holds a Federalwide Assurance for the Protection of Human Subjects may provide a genetically individualized investigational treatment to an eligible patient, and may charge the costs of manufacture. Both are patient-access statutes running through manufacturers, treating physicians, and research-grade facilities; neither authorizes a clinic to offer a standing treatment. Separately, 63 O.S. 1-270.2, part of the Advancement in Stem Cell Cures and Therapies Act, permits stem cell research using adult, cord blood, and amniotic fluid cells with Department of Health reporting, and 63 O.S. 2175 establishes the public umbilical cord blood bank at the University of Oklahoma Health Sciences Center. Those are research and banking statutes, not practice authorizations.
- Takes effect November 1, 2026
- Life-threatening or severely debilitating illness, attested by the treating physician
- Physician recommendation based on analysis of the patient’s genomic sequence or related molecular information
- Written informed consent with contents the statute specifies
- Treatment made available by a manufacturer operating within a facility holding a Federalwide Assurance
“drugs, biological products, or devices that are unique to and produced exclusively for use for an individual patient, based on the patient’s own genetic profile. Individualized investigational treatment includes, but is not limited to, individualized gene therapy antisense oligonucleotides (ASO) and individualized neoantigen vaccines”
How this applies to exosomes
None of Oklahoma’s statutes in this area reaches exosomes. The right to try acts are written around investigational drugs, biological products, and devices for gravely ill patients, provided through manufacturers and, from November 2026, facilities holding a Federalwide Assurance; an aesthetic practice is not that channel, and the acts neither name nor define extracellular vesicles. The stem cell statute at 63 O.S. 1-270.2 authorizes research with state reporting, and its subject is cells, where exosomes are acellular. There is therefore no Oklahoma definition that reads exosomes in or out, and a state access statute is in any case not an FDA approval. Exosome products are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Oklahoma practice
Since November 2025 there are two APRN prescribing structures to plan around. An APRN who has not been granted independent authority maintains a supervising physician agreement and reports a change of supervising physician to the Board of Nursing within 30 days. An APRN granted independent prescriptive authority under HB 2298 no longer files a supervising physician agreement. Physician assistant arrangements run through the Board of Medical Licensure and Supervision.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Oklahoma State Board of Medical Licensure and Supervision may perform medical acts within their scope and are the source of any delegation to staff who do not hold their own authority. The same board licenses physician assistants. |
| NP / APRN | Oklahoma APRNs practice within APRN scope, and prescriptive authority is the regulated piece. The default is supervised prescriptive authority under an agreement with a supervising physician filed with the Board of Nursing. HB 2298 (2025), enacted over the Governor’s veto and effective November 1, 2025, lets an APRN-CNP, APRN-CNS, or APRN-CNM with at least 6,240 hours of supervised prescriptive-authority practice apply for independent prescriptive authority, covering Schedule III through V controlled substances and carrying a malpractice insurance requirement. |
| PA | Physician assistants practice under physician delegation within the scope their delegating physician establishes, per the Board of Medical Licensure and Supervision’s rules. |
| RN | Registered nurses may perform delegated treatments within their scope, under an order from a provider with authority to issue one and after that provider has evaluated the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Oklahoma expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. In an aesthetic setting that provider is the physician, or an APRN prescribing within the authority they hold. Confirm current expectations with the Board of Medical Licensure and Supervision and the Board of Nursing, since this area is governed by board rules and interpretation.
Ownership and clinic licensing
Oklahoma’s corporate practice position rests on its professional entity law and board enforcement rather than a single bright-line statute, and medical practices are ordinarily organized as professional entities owned by licensees, with management services arrangements handling business operations. Because the doctrine is assembled from several sources rather than one, published summaries vary, and ownership structure for an Oklahoma med spa or aesthetic practice is a question for Oklahoma counsel and the Board of Medical Licensure and Supervision.
Cold chain into Oklahoma
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Oklahoma order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Oklahoma City | Oklahoma | Largest state market, with broad aesthetic and wellness coverage. |
| Tulsa | Tulsa | Second major metro, with an established med spa segment. |
| Edmond | Oklahoma | North Oklahoma City suburb with a dense practice corridor. |
| Norman | Cleveland | University market south of Oklahoma City. |
| Broken Arrow | Tulsa | Served alongside Tulsa on the same lane. |
- Oklahoma orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Vials arrive frozen with the manufacturer’s handling instructions and the Certificate of Analysis for the lot; follow the insert for storage on arrival.
Wholesale exosome supply by city in Oklahoma
Each city page covers local receiving conditions, delivery disruptions and business license rules for Oklahoma practices in that area.
Practice types we supply in Oklahoma
Oklahoma licensing and verification
Oklahoma State Board of Medical Licensure and Supervision
Licenses physicians and physician assistants; license lookup runs here.
Oklahoma Board of Nursing
Administers supervised and, since November 2025, independent APRN prescriptive authority.
Oklahoma State Board of Pharmacy
Licenses the wholesale distributors that ship into the state.
Oklahoma Tax Commission
Sales tax permits and resale documentation.
Oklahoma sourcing questions
- Does Oklahoma have a stem cell law?
- Not a practice law. The Advancement in Stem Cell Cures and Therapies Act, at 63 O.S. 1-270.2, permits stem cell research using adult, umbilical cord blood, and amniotic fluid cells, with annual reporting through the State Department of Health, and it was amended in 2024 only to relax that reporting. It authorizes research, not a clinical service. Oklahoma also maintains a public umbilical cord blood bank at the OU Health Sciences Center under 63 O.S. 2175, which is a banking and education statute.
- What is Oklahoma’s Right to Try for Individualized Treatments Act?
- SB 933, effective November 1, 2026, extends Oklahoma’s 2015 right to try framework to individualized investigational treatments: drugs, biologics, or devices produced exclusively for one patient from their own genetic profile, such as individualized antisense oligonucleotides or neoantigen vaccines. Access runs through a manufacturer operating within a facility that holds a Federalwide Assurance, for patients with life-threatening or severely debilitating illness, with written informed consent.
- Does Oklahoma’s right to try framework cover exosomes?
- No. Both acts are written around investigational products for gravely ill patients, supplied through manufacturers and research-grade facilities, and neither names or defines extracellular vesicles. A state access statute is also not an FDA approval. No exosome product is FDA approved for administration to humans, and ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners.
- Are exosome products FDA approved?
- No exosome product is FDA approved for administration to humans, and the FDA has issued a public safety notification about clinics marketing unapproved exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot documentation on every vial.
- Can an Oklahoma nurse practitioner prescribe without a physician?
- Since November 1, 2025, yes, by application. HB 2298, enacted over the Governor’s veto, lets an APRN-CNP, APRN-CNS, or APRN-CNM with at least 6,240 hours of supervised prescriptive-authority practice apply to the Board of Nursing for independent prescriptive authority, covering Schedule III through V, with a malpractice insurance requirement. Until that authority is granted, the APRN maintains a supervising physician agreement.
- Does my Oklahoma clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale distributor license under the Oklahoma Pharmacy Act and Okla. Admin. Code 535:20-7 is held by the distributor shipping into Oklahoma, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- How long does cold-chain shipping take to Oklahoma?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Oklahoma State Board of Pharmacy (accessed 16 October 2026)
- Oklahoma State Board of Pharmacy, laws and rules (accessed 16 October 2026)
- 63 O.S. § 1-270.2, permissible stem cell research (OSCN) (accessed 16 October 2026)
- 63 O.S. § 3091.1, Right to Try Act, short title (OSCN) (accessed 16 October 2026)
- 63 O.S. § 3092.2, Right to Try for Individualized Treatments Act, definitions (OSCN) (accessed 16 October 2026)
- Oklahoma Board of Nursing, independent prescriptive authority (HB 2298) (accessed 16 October 2026)
- Oklahoma State Board of Medical Licensure and Supervision (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The field’s current characterization standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page says accompanies every Oklahoma shipment.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark EV characterization standard, the baseline this page assumes when it describes what a defensible exosome COA reports for identity and purity.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products in trials, which frames this page’s point that investigational access statutes are not product approvals.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.